Skip to content
TrialMatch
Sign up
Recruiting

Using Light Therapy for Mild Cognitive Impairment

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks? * Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage? * Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation. Participants will: * Receive a 20-minute-long active tPBM or sham stimulation session once per day, 6 times per week, for 12 weeks. * Complete questionnaires and an iPad-based cognitive testing protocol. * Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Dynamic analysis of the vessels in the eye will also be performed based on eligibility. Transcranial Doppler (TCD) flowmetry is optionally performed. * Provide blood samples to test for biomarkers of inflammation, oxidative stress, and brain cell damage.

Condition
Mild Cognitive Impairment (MCI), Amyloid Pathology
Tested
Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham tra...
Sponsor
University of Oklahoma

Who can join

Age
55 to 95 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 8

  • Minimum age: 55 years
  • Maximum age: 95 years
  • Study condition: Mild Cognitive Impairment (MCI), Amyloid Pathology
  • Age: 55-95 years of age
  • Clinical Dementia Rating (CDR) equal to 0.5 and/or Montreal Cognitive Assessment (MoCA) \<26 and ≥19
  • Adequate hearing and visual acuity to participate in the examinations
  • English speaker
  • Presence of cerebrovascular pathology confirmed by structural brain imaging method

Exclusion 10

  • Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
  • Cerebrovascular accident other than TIA within 60 days prior to Visit 0
  • Diagnosis of amyloid angiopathy
  • Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse
  • Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia
  • Patients currently using commercial brain stimulation / neuromodulation device as part of a research study
  • Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin
  • Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\>160/100 mmHg)
  • Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol
  • Severe sensory deficits interfering with the testing

Where

1 site, 1 recruiting

University of Oklahoma Health Campus

Oklahoma City, Oklahoma, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.